Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITHER: Anti-telomerase Th1 Responses in PD-1/PD-L1 Therapy
NCT02840058Completed
- Sponsor
- CHU de Besançon
- Start
- Aug 2016
- Primary completion
- Jul 2024
- Countries
- 1
01
Overview
Open-label trial in cancer, sponsored by CHU de Besançon. Primary endpoints: Anti-telomerase specific T helper 1 responses at 12 months and Objective Response Rate at 12 months. Started Aug 2016; status: completed.
02
Conditions
cancer
Beyond the preview
Go deeper on NCT02840058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02840058.